HSIC icon

Henry Schein

69.82 USD
+0.87
1.26%
At close Dec 20, 4:00 PM EST
After hours
69.82
+0.00
0.00%
1 day
1.26%
5 days
-8.72%
1 month
-5.30%
3 months
-1.87%
6 months
4.91%
Year to date
-7.60%
1 year
-4.88%
5 years
4.74%
10 years
29.49%
 

About: Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology & value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology & other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.

Employees: 26,000

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

478% more call options, than puts

Call options by funds: $24.6M | Put options by funds: $4.26M

60% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 8 (+3) [Q3]

14% more capital invested

Capital invested by funds: $8.24B [Q2] → $9.38B (+$1.15B) [Q3]

0.22% more ownership

Funds ownership: 100.35% [Q2] → 100.57% (+0.22%) [Q3]

5% less funds holding

Funds holding: 548 [Q2] → 522 (-26) [Q3]

25% less repeat investments, than reductions

Existing positions increased: 167 | Existing positions reduced: 222

33% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 80

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$74
6%
upside
Avg. target
$77
10%
upside
High target
$82
17%
upside

3 analyst ratings

positive
33%
neutral
67%
negative
0%
Mizuho
Steven Valiquette
20% 1-year accuracy
1 / 5 met price target
7%upside
$75
Neutral
Initiated
4 Dec 2024
Barrington Research
Michael Petusky
43% 1-year accuracy
29 / 68 met price target
17%upside
$82
Outperform
Maintained
6 Nov 2024
Evercore ISI Group
Ross Muken
0% 1-year accuracy
0 / 5 met price target
6%upside
$74
In-Line
Maintained
8 Oct 2024

Financial journalist opinion

Based on 8 articles about HSIC published over the past 30 days

Positive
Zacks Investment Research
2 days ago
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
Investors are optimistic about HSIC owing to the performance of its dental business.
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
Neutral
Business Wire
4 days ago
Henry Schein to Participate at J.P. Morgan's Healthcare Investor Conference
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein to participate at J.P. Morgan's Healthcare Investor Conference.
Henry Schein to Participate at J.P. Morgan's Healthcare Investor Conference
Positive
Zacks Investment Research
1 week ago
Here's Why Henry Schein (HSIC) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Henry Schein (HSIC) is a Strong Value Stock
Positive
Zacks Investment Research
2 weeks ago
Henry Schein (HSIC) Up 6.4% Since Last Earnings Report: Can It Continue?
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?
Henry Schein (HSIC) Up 6.4% Since Last Earnings Report: Can It Continue?
Positive
Zacks Investment Research
3 weeks ago
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
Positive
CNBC
4 weeks ago
Activist Ananym has a list of suggestions for Henry Schein. How the firm can help improve profits
Ananym Capital is calling for changes at Henry Schein, which may help the company improve its profitability.
Activist Ananym has a list of suggestions for Henry Schein. How the firm can help improve profits
Positive
Zacks Investment Research
4 weeks ago
HSIC Stock Likely to Gain From Its Latest Acquisition of Acentus
Henry Schein inked a new agreement to acquire Acentus to enhance its ability to deliver CGM products directly to patients' homes.
HSIC Stock Likely to Gain From Its Latest Acquisition of Acentus
Neutral
Business Wire
4 weeks ago
Henry Schein to Participate in Investor Conferences in December
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein to participate in investor conferences in December.
Henry Schein to Participate in Investor Conferences in December
Neutral
Business Wire
1 month ago
Henry Schein to Acquire Acentus, a Leading Supplier of Homecare Medical Products
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein to acquire Acentus, a leading supplier of homecare medical products.
Henry Schein to Acquire Acentus, a Leading Supplier of Homecare Medical Products
Negative
Reuters
1 month ago
Exclusive: Activist investor Ananym Capital pushes for changes at Henry Schein, sources say
Activist investor Ananym Capital Management is urging healthcare products distributor Henry Schein to refresh its board, cut costs, tackle succession planning and consider selling its medical distribution business, sources close to matter said on Monday.
Exclusive: Activist investor Ananym Capital pushes for changes at Henry Schein, sources say
Charts implemented using Lightweight Charts™